Ethyl 3-(6-chloropyridin-3-yl)-3-oxopropanoate, 95%, 1g

5-Benzylsulfanyl-[1,2,3]thiadiazole, 95.0%, 5g

(5-(Hydroxymethyl)pyridin-3-yl)boronic acid, 95.0%, 250mg

2,5-Dioxopyrrolidin-1-yl 2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azaicosan-20-oate, 99%, 100mg

4-Chloro-2-fluoro-3-methoxybenzoic acid, 95.0%, 250mg

Methyl 2-methyl-4-oxo-4,5,6,7-tetrahydrobenzofuran-3-carboxylate, 98%, 500mg

1-Benzhydryl-N-methylazetidin-3-amine, 95.0%, 1g

Antimony(III) chloride, min. 99%, pa, ACS, 500 g, plastic packaging.

2-Ethylpyridine>98.0%(GC)(T)500mL

N-{9-[(2R,3R,4R,5R)-5-{[bis(4-methoxyphenyl)(phenyl)methoxy]methyl}-3-fluoro-4-hydroxyoxolan-2-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-2-methylpropanamide, 97%, 10g

2-tert-Butyl 5-methyl 7-oxa-2-azaspiro[3.5]nonane-2,5-dicarboxylate, 98%, 250mg

LISINOPRIL DIHYDRATE, 95%, 25g

Ethyl 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate>96.0%(GC)(T)5g